

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number:

12695.13USD2

Application Number:

10/729,276

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: HAQUE ET AL.

Filing Date: 12/03/2003

Group Art Unit: UNKNOWN

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PS	3,206,463	09/14/1965	Baetz	260	295	
PS	3,910,921	10/07/1975	Esanu	260	280R	
PS	3,987,177	10/19/1976	Giudicelli et al.	424	207	
PS	4,032,534	06/28/1977	Chodkiewicz	260	306.7 C	
PS	4,036,844	07/19/1977	Thorne et al.	260	295 R	
PS	4,053,607	10/11/1977	Thorne et al.	424	263	
PS	4,137,316	01/30/1979	Esanu	424	256	
PS	4,167,562	09/11/1979	Evers	424	153	
PS	4,361,570	11/30/1982	Fici	424	263	
PS	4,369,172	01/18/1983	Schor et al.	424	19	
PS	4,374,841	02/22/1983	Descamps et al.	424	263	
PS	4,515,771	05/07/1985	Fine	424	52	
PS	4,567,179	01/28/1986	Lombardino	514	225	
PS	4,569,938	02/11/1986	Esanu	514	802	
PS	4,569,939	02/11/1986	Esanu	514	302	
PS	4,581,363	04/08/1986	Esanu	514	302	
PS	4,605,741	08/12/1986	Zagnoli et al.	546	24	
PS	4,730,042	03/08/1988	Hege et al.	544	124	
PS	4,735,950	04/05/1988	Esanu	514	302	
PS	4,735,956	04/05/1988	Baldwin et al.	514	338	
PS	4,837,239	06/06/1989	Benjamin et al.	514	267	
PS	4,843,071	06/27/1989	Hohenwarter	514	217	
PS	4,962,121	10/09/1990	Hamberger et al.	514	419	
PS	5,001,115	03/19/1991	Sloan	514	34	
PS	5,053,396	10/01/1991	Blass	514	45	
PS	5,118,505	06/02/1992	Költringer	424	195.1	
PS	5,130,324	07/14/1992	Ulrich et al.	514	257	
PS	5,132,115	07/21/1992	Wolter et al.	424	448	
PS	5,210,083	05/11/1993	Pfirmann	514	222.5	

EXAMINER

P. SPINACK

DATE CONSIDERED

4/11/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

PS	5,213,813	05/25/1993	Kornecki et al.	424	532
PS	5,254,557	10/19/1993	Buckle et al.	514	264
PS	5,254,572	10/19/1993	Serfontein	514	345
PS	5,272,165	12/21/1993	Ulrich et al.	514	357
PS	5,278,154	01/11/1994	Lacoste et al.	514	114
PS	5,288,716	02/22/1994	Speck	514	89
PS	5,326,757	07/05/1994	Demopoulos	514	167
PS	5,328,453	07/12/1994	Sibalis	604	20
PS	5,372,999	12/13/1994	Schneider et al.	514	81
PS	5,385,937	01/31/1995	Stamler et al.	514	557
PS	5,420,112	05/30/1995	Lewis et al.	514	12
PS	5,441,972	08/15/1995	Ogata et al.	514	342
PS	5,504,090	04/02/1996	Neely	514	263
PS	5,563,126	10/08/1996	Allen et al.	514	52
PS	5,569,459	10/29/1996	Shlyankevich	424	195.1
PS	5,569,648	10/29/1996	Lewis et al.	514	12
PS	5,631,271	05/20/1997	Serfontein	514	345
PS	5,633,228	05/27/1997	Lewis et al.	514	12
PS	5,648,335	07/15/1997	Lewis et al.	514	12
PS	5,728,684	03/17/1998	Cheng et al.	514	50
PS	5,733,884	03/31/1998	Barbul et al.	514	21
PS	5,733,916	03/31/1998	Neely	514	262
PS	5,770,215	06/23/1998	Moshyedi	424	440
PS	5,795,873	08/18/1998	Allen	514	52
PS	5,804,163	09/08/1998	Gibby et al.	424	936.1
PS	5,804,594	09/08/1998	Murad	514	474
PS	5,833,998	11/10/1998	Biedermann et al.	424	401
PS	5,834,446	11/10/1998	Dow et al.	514	58
PS	5,840,685	11/24/1998	Fujii et al.	514	12
PS	5,847,008	12/08/1998	Doebber et al.	514	708
PS	5,858,017	01/12/1999	Demopulos et al.	604	840.1

EXAMINER	P. Spivack	DATE CONSIDERED	4/1/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

PS	5,859,051	01/12/1999	Adams et al.	514	469	
PS	5,874,420	02/23/1999	Pelleg	514	81	
PS	5,874,443	02/23/1999	Kiely et al.	614	304	
PS	5,888,514	03/30/1999	Weisman	424	145.1	
PS	5,944,020	08/31/1999	Markov et al.	128	848	
PS	6,043,259	03/28/2000	Dhalla et al.	514	345	
PS	6,310,093	10/30/2001	Newcomb	514	446	
PS	6,339,085	01/15/2002	Haque	514	233.8	
PS	6,586,414 B2	07/01/2003	Haque et al.	514	89	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PS	831,350	01/14/1976	BE				X
PS	863,754	05/29/1978	BE				X
PS	561 183	04/30/1975	CH				X
PS	1 958 226	05/27/1970	DE				X
PS	37 05 549 A1	09/01/1988	DE				X
PS	43 44 751 A1	06/29/1995	DE				X
PS	24 61 742 A	07/08/1976	DT				X
PS	0 121 036 A1	10/10/1984	EP				
PS	0 144 051 A2	06/12/1985	EP				
PS	0 270 026 A2	06/08/1988	EP				
PS	0 416 248 A2	03/13/1991	EP				
PS	0 891 719 A1	01/20/1999	EP				
PS	846,376	03/26/1941	FR				X
PS	1,323,941	12/15/1963	FR				X
PS	5,552 M	12/26/1967	FR				X
PS	5,801 M	03/28/1968	FR				X
PS	6,453 M	12/16/1968	FR				X
PS	1,579,544	08/29/1969	FR				X

EXAMINER	P. SPINACK	DATE CONSIDERED	4/11/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

PS	22-034 539	12/11/1970	FR				X
PS	2,101,010	03/31/1972	FR				X
PS	2,255,883	07/25/1975	FR				X
PS	2,428,640	01/11/1980	FR				X
PS	1 013 939	12/22/1965	GB				
PS	1,172,800	12/03/1969	GB				
PS	1 201 014	08/05/1970	GB				
PS	1 297 080	11/22/1972	GB				
PS	1 360 536	07/17/1974	GB				
PS	1 493 993	12/07/1977	GB				
PS	2 254 556 A	10/14/1992	GB				
	48-21959	07/02/1973	JP				X
PS	54-17130	02/08/1979	JP				X
PS	WO 83/00085	01/20/1983	PCT				
PS	WO 91/19500	12/26/1991	PCT				Abstract
PS	WO 94/18965	09/01/1994	PCT				
PS	WO 98/19690	05/14/1998	PCT				
PS	WO 99/03365	01/28/1999	PCT				
PS	WO 99/53928	10/28/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PS	Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension", <i>Drug Res.</i> , Vol. 45, No. 12, pp. 1271-1273 (1995).
PS	"B Vitamins May Cut Heart Disease Risk", <i>Harvard Health Letter</i> , 1 page (1998).
PS	Baliga, B. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine", <i>Endocrine Practice</i> , Vol. 6, No. 6, pp. 435-441 (November/December 2000).
PS	Barrett, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quackwatch.com/03HealthPromotion/homocysteine.html , 2 pages (©1997).
PS	Bernstein, A., "Vitamin B ₆ in Clinical Neurology", <i>Annals of New York Academy of Sciences</i> , Vol. 585, pp. 250-260 (1990).
PS	Berger, A.R. et al., "Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", <i>Neurology</i> , Vol. 42, No. 7, pp. 1367-1370 (July 1992).
PS	Bhagavan, H. et al., "Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5'-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", <i>Pediat. Res.</i> , Vol. 10, pp. 730-732 (1976).

EXAMINER	P. Spivack	DATE CONSIDERED	4/1/06
EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number:	Application Number:
	12695.13USD2	10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

PS	Bode, W. et al., "Pyridoxal-5'-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", <i>J. Nutr.</i> , Vol. 121, No. 11, pp. 1738-1745 (November 1991).
	Broff H. et al., "New Aspects in the Treatment of Cerebral Ischemia", <i>Weiner Medizinische Wochenschrift</i>, Vol. 125, No. 45, pp. 646-650 (1975)
PS	Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B ₆ and Risk of Myocardial Infarction in US Physicians", <i>Journal of the American College of Nutrition</i> , Vol. 15, No. 2, pp. 136-143 (April 1996).
PS	Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", <i>J. Nutr.</i> , Vol. 120, pp. 258-265 (1990).
	"Computer Generated Search Reports", 70 pages (May 1999)
PS	Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B ₆ ", <i>Res. Commun. Molec. Pathol. Pharmacol.</i> , Vol. 89, No. 2, pp. 208-220 (August 1995).
PS	Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", <i>Circulation</i> , Vol. 98, pp. 204-210 (July 21, 1998).
PS	Harada, K. et al., "Studies on Vitamin B ₆ (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", <i>Vitamins Journal of the Vitamin Society of Japan</i> , Vol. 45, No. 2, pp. 69-75 (February 1972)
PS	Hathcock, J., "Vitamins and minerals: efficacy and safety", <i>Am J Clin Nutr</i> , Vol. 66, pp. 427 - 437 (1997)
PS	Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", <i>Vet. Pathol.</i> , Vol. 18, pp. 769-777 (1981)
PS	Kok, F. et al., "Low Vitamin B ₆ Status in Patients with Acute Myocardial Infarction", <i>Am. J. Cardiol.</i> , Vol. 63, pp. 513-516 (March 1, 1989)
PS	Korytnyk et al. Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, <i>Tetrahedron</i> , 26 (23), 5415-25 (1982),
PS	Krinke, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B ₆ in Rat Primary Sensory Neurons", <i>J. Neuropathol. Exp. Neurol.</i> , Vol. 44, No. 7, pp. 117-129 (March 1985).
PS	Kubyskhin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", <i>Abstract</i> , 1 pg. (1989), pp. 82-85.
PS	Lal, K. et al., "Hypotensive action of 5-HT receptor agonists in the vitamin B ₆ -deficient hypertensive rat", <i>Eur. J. Pharmacol.</i> , Vol. 234, Nos. 2/3, pp. 183-189 (April 1993).
PS	Lal, K. et al., "Calcium channels in vitamin B₆ deficiency-induced hypertension", <i>Journal of Hypertension</i>, Vol. 11, No. 12, pp. 1357-1362 (December 1993)
PS	Lal, K. et al., "The effect of vitamin B ₆ on the systolic blood pressure of rats in various animal models of hypertension", <i>Journal of Hypertension</i> , Vol. 14, No. 3, pp. 355-363 (March 1996).
PS	Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", <i>P.S.E.B.M.</i> , Vol. 101, pp. 617-621 (1959).
PS	Manore, M. et al., "Changes In Plasma Pyridoxal Phosphate (PLP) In Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet", <i>Source Unknown</i> , pp. 1254 (1990).
PS	Markov, A. et al, "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia", <i>American Heart Journal</i> , Vol. 100, No. 5, pp. 639 - 646 (November 1980).
PS	Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", <i>JACC</i> , Vol. 30, No. 1, pp. 237-242 (July 1997).
PS	Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B ₆ metabolism or utilization", <i>Ann. Rev. Nutr.</i> , Vol. 7, pp. 137-156 (1987).

EXAMINER	P. Spivack	DATE CONSIDERED	4/1/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

PS	Mulvaney, D. et al., "Electrocardiographic changes in vitamin B ₆ deficient rats", <i>Cardiovascular Research</i> , Vol. 13, pp. 506-513 (1979).
PS	Omenn, G. et al., "Preventing Coronary Heart Disease", <i>Circulation</i> , Vol. 97, pp. 421-424 (1998) .
PS	Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", <i>Hypertension</i> , Vol. 11, No. 4, pp. 387-391 (April 1988) .
PS	Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", <i>Journal of Clinical Endocrinology & Metabolism</i> , Vol. 50, No. 1, pp. 198-200 (January 1980).
PS	Rimm, E. et al., "Folate and Vitamin B ₆ From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", <i>JAMA</i> , Vol. 279, No. 5, pp. 359-364 (February 4, 1998) .
PS	Sakuragi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B ₆ Group", <i>J. Am. Chem. Soc.</i> , Vol. 78, pp. 839-842 (February 20, 1956).
PS	Sethi, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", <i>The American Physiological Society</i> , Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997) .
PS	Sethi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats", <i>Journal of Cardiac Failure</i> , Vol. 1, No. 5, pp. 391 - 399 (December 1995) .
PS	Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Corticotropin", <i>Journal of Child Neurology</i> , Vol. 11, No. 1, pp. 35-40 (January 1996) .
PS	Tanaka, T. et al., "Pyridoxine Derivatives", <i>Chemical Abstracts</i> , Vol. 62, No. 12, 1 page (June 7, 1965) .
PS	Treize, D. et al., "P ₂ purinoceptor antagonist properties of pyridoxal-5-phosphate", <i>Eur. J. Pharmacol.</i> , Vol. 259, No. 3, pp. 295-300 (July 11, 1994) .
PS	Vanderjagt, D. et al., "Vitamin B ₆ Status in a Healthy Elderly Population", <i>Annals New York Academy of Sciences</i> , pp. 562 - 564 (1990) .
PS	Verhoef, P. et al., "A Common Mutation in the Methylenetetrahydrofolate Reductase Gene and Risk of Coronary Heart Disease: Results Among U.S. Men", <i>JACC</i> , Vol. 32, No. 2, pp. 353 -359 (August 1998) .
PS	Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B ₆ , B ₁₂ , and Folate", <i>Am. J. Epidemiol.</i> , Vol. 143, No. 9, pp. 845-859 (May 1, 1996) .
PS	Vermaak, W.J.H. et al., "Vitamin B ₆ and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 235-238 (February 1987)
PS	Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 15, pp. 150-156 (1990).
PS	Viscontini, V. et al., "Über einige Derivate des Pyridoxals", <i>Helvetica Chimica Acta</i> , Vol. 34, No. 296, pp. 2438-2439 (1951) .
PS	Volpe, J.J., "Management of Neonatal Seizures", <i>Critical Care Medicine</i> , Vol. 5, No. 1, pp. 43-49 (Jan-Feb 1977) .
PS	Windebank, A., "Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure", <i>Neurochemical Pathology</i> , Vol. 3, pp. 159-167 (1985) .
PS	Yarat, A. et al., "Effect of vitamin B ₆ on lenses of diabetic rats", <i>Indian Journal of Experimental Biology</i> , Vol. 36, pp. 1269-1272 (December 1998) .
PS	Zempleni, J. et al., "The utilization of intravenously infused pyridoxine in humans", <i>Clinica Chimica Acta</i> , Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994) .

EXAMINER	P. Spivack	DATE CONSIDERED	4/1/06
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,339,085	01/15/2002	Haque			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		

23552 PATENT TRADEMARK OFFICE

duplicate

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	